Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
Christopher J. Sweeney, Andrew Martin, Martin R. Stockler, Stephen Begbie, Kim N., Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy Hague, Lisa G. Horvath, Anthony M. Joshua, Nicola Jane Lawrence, Gavin Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott North, Francis Parnis, Wendy R. Parulekar, David Pook, M. Neil Reaume, Shahneen Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Emily Tu, Francisco Vera-Badillo, Scott Williams, Sonia Yip, Alison Y. Zhang, Robert Zielinski, Ian D. Davis
Topics & Concepts
MedicineEnzalutamideProstate cancerHazard ratioAndrogen deprivation therapyOncologyInternal medicineHormonal therapyHormone therapyInterim analysisProstateCancerConfidence intervalUrologyClinical trialBreast cancerAndrogen receptorProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsCancer, Lipids, and Metabolism